About CytoSite Bio
CytoSite Bio is a company based in United States founded in 2016 by Benjamin Larimer, Jim Jenson, Umar Mahmood, and Eric Wehrengerg Klee. CytoSite Bio has raised $7.49 million across 4 funding rounds from investors including HHS. CytoSite Bio offers products and services including Granzyme B PET Agent and PET Imaging Protocol. CytoSite Bio operates in a competitive market with competitors including Denali Therapeutics, Poseida Therapeutics, Castle Biosciences, Juno Therapeutics and Personalis, among others.
- Headquarter United States
- Founders Benjamin Larimer, Jim Jenson, Umar Mahmood, Eric Wehrengerg Klee
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$7.49 M (USD)
in 4 rounds
-
Latest Funding Round
$3.05 M (USD), Series A
Sep 24, 2020
- Investors
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of CytoSite Bio
CytoSite Bio offers a comprehensive portfolio of products and services, including Granzyme B PET Agent and PET Imaging Protocol.
PET agent for detecting immune cell activation in cancer immunotherapy monitoring.
Protocol for non-invasive immune response evaluation in clinical trials.
Funding Insights of CytoSite Bio
CytoSite Bio has successfully raised a total of $7.49M across 4 strategic funding rounds. The most recent funding activity was a Series A round of $3.05 million completed in September 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in CytoSite Bio
CytoSite Bio has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include HHS.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Public health and human services are overseen by HHS.
|
Locked | Locked | Locked |
Investor details for CytoSite Bio
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by CytoSite Bio
Investment portfolio details for CytoSite Bio
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - CytoSite Bio
Detailed financials for CytoSite Bio
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Cytosite Bio Comparisons
Peer comparison for CytoSite Bio
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of CytoSite Bio
CytoSite Bio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Denali Therapeutics, Poseida Therapeutics, Castle Biosciences, Juno Therapeutics and Personalis, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's.
|
|
| Locked | Locked | Locked |
Developer of gene therapies for treating cancer and liver orphan disease by using gene editing technologies
|
|
| Locked | Locked | Locked |
Precision diagnostic and prognostic tests are developed by Castle Biosciences.
|
|
| Locked | Locked | Locked |
CAR T-cell and T-cell receptor immunotherapies for cancer are developed.
|
|
| Locked | Locked | Locked |
Genomic sequencing and diagnosis software is provided for healthcare.
|
|
| Locked | Locked | Locked |
Therapeutics for aging diseases are developed by targeting senescent cells.
|
Detailed competitors of CytoSite Bio
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Cytosite Bio
Complete news archive for CytoSite Bio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about CytoSite Bio
CytoSite Bio was founded in 2016 and raised its 1st funding round 1 year after it was founded.
CytoSite Bio is headquartered in United States.
Jim Jenson is the current CEO of CytoSite Bio. They have also founded this company.
CytoSite Bio is a funded company, having raised a total of $7.49M across 4 funding rounds to date.
CytoSite Bio was founded in 2016 in the United States and operates in the biotechnology sector focused on immuno-oncology. Precision imaging products are developed to detect active T-cell or NK cell activity through Granzyme B, which targets tumor cell killing by the immune system. These tools enable optimization of patient immunotherapy regimens by providing insights into treatment efficacy. The companys operations center on advancing diagnostic technologies for clinical use.
CytoSite Bio's top competitors include Juno Therapeutics, Personalis and Poseida Therapeutics.
CytoSite Bio offers Granzyme B PET Agent and PET Imaging Protocol.
CytoSite Bio has 1 investor. Key investors include HHS.